Inside Thryv - A Conversation with Doug Wight, Vice President, Drug Development
Introducing Doug Wight, Thryv's Vice President, Drug Development. Join us as Doug shares his impactful journey in the field of life sciences that lead him to his pivotal role in drug development at Thryv!
Inside Thryv - A Conversation with Marc Vidal, Senior Director, Product & Process Development
Join us as we introduce Marc Vidal, our Senior Director of Product & Process Development at Thryv. Discover Marc’s journey in the sciences, how it lead him to be the first employee to join the Thryv team, and learn how he consistently works to #berelentless in pursuit of innovation!
Inside Thryv - A Conversation with Shannon Hewgill, Research Associate
Curious about the behind-the-scenes of Thryv's oncology program development? Meet Shannon Hewgill, our Research Associate who's work in the lab is helping develop the oncology program from the ground up.
Inside Thryv - A Conversation with Debra Odink, President & CDO
In our new series, ‘Inside Thryv - Conversations with Employees,’ we sit down with our team members to learn about their roles and how they help drive our mission forward. First up is Thryv’s President & Chief Development Officer, Debra Odink!
SADS Live interview with Thryv Therapeutics
Three of our team were invited to join Dr. Michael Ackerman as part of the SADS Live program. We invite you to watch this interview to learn more about our passionate team and progress, what the next steps are as we move into clinical studies, and what we are doing to challenge the current LQTS treatments.
What a great year we had at Thryv!
2022 was a big year for Thryv Therapeutics, and 2023 is shaping up to be even bigger. Debra Odink, President & Chief Development Officer, shares her wrap-up of the year.
Racing for a Cure for Long QT Syndrome: A Day with Dr. Das
Dr. Saumya Das, PhD MD, answers some tough questions about his research and the difficulties of treating individuals with a chronic syndrome.
How Many LQTS Patients are There?
LQTS has a very real impact. At a rate of 1 in 2,500 newborns, prevalence could be north of 130,000 people in the USA alone. Most importantly, we have the ability, and perhaps the moral obligation, to diagnose LQTS and uncover individuals born with it.
Long QT Syndrome and Its Various Types
Long QT Syndrome is a relatively rare heart rhythm disorder. It affects the heart’s electrical system, resulting in abnormal electrical activity that can cause potentially fatal rapid heart rates and rhythms. There are various types of LQTS, and this article provides an overview of them.
Why SGK1 May Be the Key to Unlocking Advanced LQTS Treatments
SGK-1’s neuronal excitability and its effect in action potential morphology (APM) of cardiomyocytes has captured the full attention of our scientists.
Dr. Maroua Khalifa, Ph.D
Dr. Maroua Khalifa Ph.D is a research scientist reviewing chemistry and biology reports, designing new molecules and their synthetic routes to target specific biological pathways, and developing and executing multi-step synthesis of new small molecules.